NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · IEX Real-Time Price · USD
8.17
-0.39 (-4.56%)
At close: May 17, 2024, 4:00 PM
8.22
+0.05 (0.61%)
After-hours: May 17, 2024, 4:59 PM EDT
NeuroPace Revenue
NeuroPace had revenue of $69.07M in the twelve months ending March 31, 2024, with 42.07% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $18.12M with 25.23% year-over-year growth. In the year 2023, NeuroPace had annual revenue of $65.42M with 43.72% growth.
Revenue (ttm)
$69.07M
Revenue Growth
+42.07%
P/S Ratio
3.39
Revenue / Employee
$403,936
Employees
171
Market Cap
233.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
Dec 31, 2019 | 36.97M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 301.87M |
AirSculpt Technologies | 197.72M |
G1 Therapeutics | 84.04M |
Utah Medical Products | 49.04M |
Foghorn Therapeutics | 33.90M |
uniQure | 19.00M |
Adaptimmune Therapeutics | 18.36M |
NPCE News
- 9 days ago - NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 - GlobeNewsWire
- 7 weeks ago - NeuroPace to Present at the Needham 23rd Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million - GlobeNewsWire
- 3 months ago - NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 - GlobeNewsWire
- 4 months ago - NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates - GlobeNewsWire
- 5 months ago - NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study - GlobeNewsWire
- 5 months ago - NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire